Clinical Trial: Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Ranibizumab vs PDT for Presumed Ocular Histoplasmosis

Brief Summary: The purpose of this study is to evaluate the change in visual activity of ranibizumab to Photodynamic Therapy (PDT)in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis

Detailed Summary:
Sponsor: Barnes Retina Institute

Current Primary Outcome: Mean change in visual acuity [ Time Frame: 6 months, 1 year ]

Original Primary Outcome: Mean change in visual acuity on the ETDRS chart at 4 meters of ranibizumab patients vs PDT patients from baseline to 1 year [ Time Frame: 1 year ]

Current Secondary Outcome: To evaluate mean change in vision at 6 months [ Time Frame: 6 months ]

Original Secondary Outcome: Same as current

Information By: Barnes Retina Institute

Dates:
Date Received: October 17, 2007
Date Started: October 2007
Date Completion: April 2010
Last Updated: April 15, 2009
Last Verified: April 2009